InspireMD Inc. (NSPR): Price and Financial Metrics

InspireMD Inc. (NSPR): $1.91

0.18 (-8.61%)

POWR Rating

Component Grades








NSPR Price/Volume Stats

Current price $1.91 52-week high $3.85
Prev. close $2.09 52-week low $1.00
Day low $1.87 Volume 21,300
Day high $2.14 Avg. volume 34,804
50-day MA $2.44 Dividend yield N/A
200-day MA $2.88 Market Cap 44.80M

NSPR Stock Price Chart Interactive Chart >

InspireMD Inc. (NSPR) Company Bio

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. is headquartered in Tel Aviv, Israel.

NSPR Latest News Stream

Event/Time News Detail
Loading, please wait...

NSPR Latest Social Stream

Loading social stream, please wait...

View Full NSPR Social Stream

Latest NSPR News From Around the Web

Below are the latest news stories about INSPIREMD INC that investors may wish to consider to help them evaluate NSPR as an investment opportunity.

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of strokeTEL AVIV, Israel and MIAMI, Dec. 20, 2023 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the issuance of U.S. Patent No. 11,844,893, titled, “Shunts with Blood Flow Indicators.”

Yahoo | December 20, 2023

InspireMD's Gary Roubin Acquires 13% More Stock

Investors who take an interest in InspireMD, Inc. ( NASDAQ:NSPR ) should definitely note that insider Gary Roubin...

Yahoo | December 6, 2023

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

Study to enroll 15 acute stroke patients across three U.S. sitesTEL AVIV, Israel and MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the company has entered into a strategic agreement with the Jacobs Institute at the State University of New York at Buffalo, and Dr. Adnan Siddiqui, Vice-Chairman and Professor of Neurosurgery, to execute an Early Feasibility St

Yahoo | November 27, 2023

InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript

InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript November 6, 2023 InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.15, expectations were $-0.17. Operator: Good morning. And welcome to the InspireMD Third Quarter of 2023 Earnings Call. Currently, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. […]

Yahoo | November 7, 2023

InspireMD Inc (NSPR) Reports Q3 2023 Financial Results: CGuard EPS Revenue Increases by 9% ...

Positive 30-day results from C-GUARDIANS U.S. IDE clinical trial and CMS' decision to expand CAS coverage contribute to the company's growth

Yahoo | November 6, 2023

Read More 'NSPR' Stories Here

NSPR Price Returns

1-mo -19.41%
3-mo -37.38%
6-mo -41.05%
1-year 86.34%
3-year -72.52%
5-year -96.98%
YTD -32.03%
2023 226.93%
2022 -71.54%
2021 -40.94%
2020 -68.44%
2019 -86.42%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!